Global Atherosclerosis drugs Market is valued approximately at USD 2.7 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 6.16% over the forecast period 2023-2030. Atherosclerosis drugs is a therapeutic category of medications used for the treatment of atherosclerosis and related cardiovascular diseases such as heart attacks, strokes, and peripheral vascular disease. This market growth is attributed to the high consumption of cholesterol-lowering drugs by patients to reduce or avoid blockages in arteries. The increasingly fast-paced lifestyle has depleted the ordinary person’s usual diet of essential nutrients that increases the risk of atherosclerosis, despite the age group and the growth rate of atherosclerosis market is the rising healthcare expenditure which helps in improving its infrastructure. The research and development in the healthcare sector have led to the production of effective atherosclerosis drugs globally.
Increasing the risk of atherosclerosis, the increased prevalence of obesity and high cholesterol is predicted to boost the market’s growth rate. According to estimates from the World Health Organisation (WHO) in 2020, 40 million children under the age of five were overweight or obese. Increased consumption of food high in fat and sugar as well as an increase in physical immobility brought on by the fact that many jobs are becoming less physically demanding, changing transportation options and growing urbanization are the factors that contributes to high cholesterol rates in people that are driving the market’s rapid expansion. Moreover, the market’s growth is fueled by an increase in the number of research and development activities also the integration of e-Commerce and the healthcare sector will generate considerable sales potential through online pharmacies for companies in the atherosclerosis medicines market. However, Side effects of drugs and the availability of generic products are the factors expected to restrain the market growth during the forecast period.
The key regions considered for the Global Atherosclerosis drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 holding the largest market share owing to the increased frequency of atherosclerosis and technical improvement in the treatment in this region. Furthermore, increased healthcare expenditure and the presence of significant key players would drive the market development rate in this area. According to the National Centre for Chronic Disease Prevention and Health Promotion’s Division for Heart Disease and Stroke Prevention, which was updated in July 2022, one person dies from cardiovascular disease every 34 seconds in the United States. Asia Pacific is expected to grow significantly during the forecast period, owing to the growing elderly population in this area and the rising level of disposable income. Additionally, the expansion of the healthcare sector’s infrastructure and growing government efforts will accelerate the market’s expansion in this area.
Major market player included in this report are:
F. Hoffmann-La Roche Ltd.
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
Sanofi S.A.
Pfizer Inc.
GlaxoSmithKline plc
Novartis AG
Merck & Co
Allergan Plc
AstraZeneca
Recent Developments in the Market:
Ø In September 2022, Novo Nordisk has entered into a new strategic cooperation with Microsoft to accelerate medication research and development via the use of big data and artificial intelligence (AI). The team will employ artificial intelligence to construct models that can predict a person’s risk of getting atherosclerosis or arterial plaque development. The researchers will also look for new atherosclerosis targets and indicators.
Ø In August 2022, AstraZeneca and Merck, known as MSD outside the United States and Canada, announced that the European Commission (EC) has approved LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2 mutations (gBRCAm) and HER2-negative high-risk early breast cancer who have previously received neoadjuvant or adjuvant chemotherapy.
Global Atherosclerosis drugs Market Report Scope:
ü Historical Data – 2020 – 2021
ü Base Year for Estimation – 2022
ü Forecast period – 2023-2030
ü Report Coverage – Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
ü Segments Covered – Stages, Diagnosis, Treatment, Route of Administration, End-Users, Distribution Channel, Region
ü Regional Scope – North America; Europe; Asia Pacific; Latin America; Middle East & Africa
ü Customization Scope – Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Stages:
Endothelial Damage and Immune Response
Fatty Streak
Plaque Growth
Plaque Rupture
By Diagnosis:
Ankle-brachial Index
Doppler Ultrasound
Echocardiogram
Electrocardiogram
Blood Tests
Others
By Treatment:
Medication
Surgery
Others
By Route of Administration:
Oral,
Parenteral
Others
By End-Users:
Hospitals
Specialty Clinics
Homecare
Others
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa